Atherectomy System Treats Severely Calcified Coronary Lesions

The eccentrically mounted crown reduces coronary plaque while changing vessel compliance, enabling successful stent deployment; as the crown rotates and orbit increases, centrifugal force presses the crown against the lesion, reducing arterial calcium. The differential sanding allows healthy tissue to flex away. The miniscule particulates produced do not require embolic protection.

Other components of the system include the ViperWire Advance coronary guide wire to enable optimal orbital path and efficient differential sanding, while providing tactile feedback for wire navigation throughout the vessel. Proprietary ViperSlide coronary lubricant increases the lubricity, reducing friction, thus allowing for easy advancement of the device over the wire. A saline infusion pump bathes the shaft and crown with saline and ViperSlide lubricant to facilitate smooth operation of the system. The Diamondback 360 Coronary OAS is a product of Cardiovascular Systems (CSI; St. Paul, MN, USA), and has been approved by the US Food and Drug Administration (FDA).

“Today is a landmark moment for patients suffering from calcified coronary artery disease, their families, our physician operators and everyone at CSI,” said David L. Martin, president and CEO of Cardiovascular Systems. “FDA approval of our Diamondback 360 Coronary OAS allows us to bring to market the first new coronary atherectomy system in more than two decades.”

“Having a user-friendly device available to effectively treat severe coronary calcium may increase the safety of CAD interventions for this difficult to treat population, while improving long-term patient prognoses,” said Prof. Gregg Stone, MD, director of the cardiovascular research at New York Presbyterian Hospital/Columbia University Medical Center (NY, USA).

Related Links:
Cardiovascular Systems
New York Presbyterian Hospital/Columbia University Medical Center